药物化学系

首页  师资队伍  在职教师  药物化学系

冉凡胜

作者:金飞     日期:2021-10-26   点击数:2260  

师资介绍

冉凡胜,男,汉族,19925月生,博士,讲师。入选江苏省双创博士。



教育经历:

2010.09-2014.06哈尔滨师范大学,制药工程,学士

2014.09-2019.12山东大学,药物化学,博士



工作经历:

2020.06-至今 南通大学,药学院,讲师



研究方向:

药物化学



社会学术兼职:



基金项目:

  1. 江苏省高校自然科学研究项目面上项目, 22KJB350009,新型BTK/FLT3双靶点抑制剂的开发及抗类风湿性关节炎作用研究, 2022/08-2024/08,在研,主持

  2. 南通市基础科学研究计划-面上项目, JC22022096,新型BTK/FLT3双靶点抑制剂的设计、合成及抗类风湿性关节炎作用机制研究,2022/07-2024/06,结题,主持



科研成果:

5年侧重于基于靶标的小分子抗肿瘤及抗炎药物研究。以第一或通讯作者身份在Journal of Medicinal ChemistryEuropean Journal of Medicinal ChemistryBioorganic Chemistry等期刊发表专业学术论文十余篇,其中中科院JCR分区1区论文6篇,2区论文1篇,论文累积被引百余次。



成果奖励:

  1. 第十四届全国大学生“药苑论坛”创新成果一等奖

  2. 第十四届全国大学生“药苑论坛”优秀论文奖

  3. 第十三届全国大学生“药苑论坛”创新成果三等奖



代表性论文:

  1. Jianqiang Qian; Zhongyuan Xu; Chi Meng; Yun Liu; Hongmei Wu; Yunyun Wang; Jinxian Yang; Hongwei Zheng;Fansheng Ran*; Gong-Qing Liu*; Yong Ling*; Redox-Activatable Theranostic Co-Prodrug for Precise Tumor Diagnosis and Selective Combination Chemotherapy, Journal of Medicinal Chemistry, 2022, 65(15): 10393-10407.

  2. Fansheng Ran; Xudong Xie; Qilin Wu; Hongmei Wu; Yun Liu; Weizhi Tao; Yan Sun; Ruojia Wang; Yanan Zhang; Yong Ling; Development of Novel Hydrazidoarylaminopyrimidine-Based BTK/FLT3 Dual Inhibitors with Potent Anti-Hematological Malignancies Effects, European Journal of Medicinal Chemistry, 2023, 245: 114913.

  3. Ran, Fansheng; Liu, Yun; Zhu, Jian; Wu, Hongmei; Tao, Weizhi; Xie, Xudong; Hu, Yirong; Zhang, Yanan; Ling, Yong; Design, synthesis and pharmacological characterization of aminopyrimidine derivatives as BTK/FLT3 dual-target inhibitors against acute myeloid leukemia, Bioorganic Chemistry, 2023, 134: 106479.

  4. Ran, Fansheng; Liu, Yun; Xu, Zhongyuan; Meng, Chi; Yang, Dezhi; Qian, Jianqiang; Deng, Xuexian; Zhang, Yanan; Ling, Yong ; Recent development of BTK-based dual inhibitors in the treatment of cancers, European Journal of Medicinal Chemistry, 2022, 233: 114232.

  5. Ran, Fansheng; Liu, Yun; Wang, Chen; Xu, Zhongyuan; Zhang, Yanan; Liu, Yang; Zhao, Guisen; Ling, Yong; Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib, European Journal of Medicinal Chemistry, 2022, 229: 114009.